Navigation Links
Collagenase in Medical News

Bobbi Drais Promoted to Vice President, Regulatory Affairs for HEALTHPOINT, Ltd.

...approval. Ms. Drais was also instrumental in gaining regulatory approval of collagenase SANTYL(R) Ointment in Canada. "With Bobbi at the helm of all regulator...clinical and quality of life outcomes. Currently marketed products include: collagenase SANTYL(R) Ointment, OASIS(R) Wound Matrix, HYDROFERA BLUE(R) Bacteriostatic...

BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 10th Annual Healthcare Conference

...s. About BioSpecifics Technologies Corp. BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive capsulitis). It has a development and licensing ...

The Wound Institute(R) Launches Educational Course on Chronic Wound Infections

...h, development and marketing of branded biologics, pharmaceuticals, over the counter drugs, and medical devices. Current HEALTHPOINT products include: collagenase SANTYL(R) Ointment, OASIS(R) Wound Matrix, and Hydrofera Blue(TM) Bacteriostatic Wound Dressings. HEALTHPOINT is also committed to advancing the care ...
Collagenase in Medical Technology

Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing

FORT WORTH, Texas, Aug. 26 /PRNewswire/ -- Healthpoint today announced that it has initiated a clinical trial to evaluate the effectiveness of a widely prescribed enzymatic debriding agent on healing cutaneous wounds and resulting scars. The pilot study was prompted, in part, by clinical repor...

HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study

...and development of novel biologics and pharmaceuticals intended to improve clinical and quality of life outcomes. Currently marketed products include: collagenase SANTYL(R) Ointment, OASIS(R) Wound Matrix, HYDROFERA BLUE(R) Bacteriostatic Wound Dressings, and SURGICEPT(R) Waterless Surgical Hand Antiseptic. HEAL...

Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers

...and development of novel biologics and pharmaceuticals intended to improve clinical and quality of life outcomes. Currently marketed products include: collagenase SANTYL(R) Ointment, OASIS(R) Wound Matrix, HYDROFERA BLUE(R) Bacteriostatic Wound Dressings, and SURGICEPT(R) Waterless Surgical Hand Antiseptic. HEAL...

BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference

...nologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; an...Application with the U.S. Food and Drug Administration to market injectable collagenase (XIAFLEX(TM)) in the U.S. for the treatment of Dupuytren's disease, while P...

Got Pain?

...nd nerve pain, explains Dr. Osterman. But new treatments, like arthroscopy, collagenase injections, nerve wraps, desensitization techniques, therapeutic techniques... at Stony Brook School of Medicine, "injection therapy, such as Clostridial collagenase (a substance intended to reduce the collagen buildup in the palm and disrup...

Applying Clinical Findings to the Practice of Medicine

... Fibroproliferative Disorders" focused on the use of injectible Clostridial collagenase as an alternative to surgery in treating these conditions. According... standard of care is surgery." Dr. Hurst and his team injected Clostridial collagenase to the joint and reduced contractures in metacarpophalangeal and proximal i...

BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronie's Disease

...ulletin Board: BSTC), a biopharmaceutical company developing first in class collagenase based products, announced today the initiation of a U.S. Phase IIb clinical.... is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease and...

Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture

...e CORD I and CORD II phase III clinical trials for XIAFLEX(TM) (clostridial collagenase for injection) in the treatment of Dupuytren's contracture. Each of the COR...uxilium has four projects in clinical development. XIAFLEX(TM) (clostridial collagenase for injection) is in phase III of development for the treatment of Dupuytre...

Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)

...pogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX(TM) (clostridial collagenase for injection), formerly referred to as AA4500, is in phase III development for the treatment of Dupuytren's contracture and is in phase II developmen...

Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)

... hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. AA4500, an injectable collagenase enzyme, is in phase III of development for the treatment of Dupuytren's contracture and is in phase II of development for the treatment of Peyronie's ...
Collagenase in Medical Products

Permacol surgical implant

Description:... collagen that 3-D architecture is maintained. A precisely controlled degree of cross-linking is introduced into the structure, making it resistant to collagenase enzymes responsible for the breakdown and resorption of implanted collagen. This unique feature enables surgeons to complete operations and procedures...
Company:Tissue Science Laboratories Inc.

GBM -Ab EIA Auto-Immune Markers 013-GBM-48 Glomerular Basement Membrane

Description:...e of this purified antigen does not give false positive results for patient specimens containing other autoantibodies to the GBM, in contrast to crude collagenase digests of the total GBM (2). Glomerulonephritis is a major cause of irreversible renal failure. Many forms of glomerulonephritis are caused by immuno...
Company:ALPCO Diagnostics
Collagenase in Biological News

'Smart' nanoprobes light up disease

...uantum dots was cut by more than 70 percent when they were attached to the gold particles. They remained dark until the nanostructures were exposed to collagenase after which the luminescence steadily returned. Ultimately, the researchers hope to pair a series of quantum dots, each with a unique NIR optical s...
Collagenase in Biological Technology

BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009

...nologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; an...and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is respon...

BioSpecifics Technologies Corp. to Present at CapStone Investments' Third Annual Small-Cap Investor Conference

...nologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; an...and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is respon...

BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes

...nologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; an...and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is respo...

BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results

...nologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; an...and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is respo...

BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytren's Disease

... is a biopharmaceutical company that has developed and partnered injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease, an...xilium to obtain regulatory approval in the United States of the injectable collagenase product XIAFLEX for Dupuytren's and Peyronie's disease, and other factors i...

BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results

...About BioSpecifics Technologies Corp. BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and partnered injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease, and frozen shoulder (adhesive capsulitis). It has a development and licensing...

BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market

...iopharmaceutical company developing first in class collagenase based products, today announced that it has receiv...nnounced positive Phase 3 clinical results for our collagenase product XIAFLEX(TM) for Dupuytren's disease and ou...mpany that has developed and partnered, injectable collagenase for three clinical indications: Dupuytren's diseas...

Bell Ventures Launches Breakthrough Radical Defense Skin Care Ingredient

...n against 5 free radicals. Bell Ventures also uses recognized markers of skin damage to demonstrate efficacy. GlobalPAX(TM) is standardized to collagenase and elastase inhibition, evidence that it helps defend against skin damage. David Bell, President of Bell Ventures, says, "GlobalPAX(TM) is the re...

BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference

...bout BioSpecifics Technologies Corp. BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive capsulitis). It has a development and licensing ...

BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors

...iopharmaceutical company developing first in class collagenase based products, today announced the appointment of...will be invaluable to our organization as our lead collagenase product XIAFLEX(TM) moves through late-stage clini...company that has developed and licensed injectable collagenase for three clinical indications: Dupuytren's diseas...
Collagenase in Biological Products

GIBCO Collagenase Type III from Invitrogen

Description: Request Info...
Company:Invitrogen
Collagenase in Biological Dictionary

Oocytes

...from which an egg or ovum develops by meiosis; a female gametocyte. ... Oocytes are rich in cytoplasm which contains yolk granules to ... collagenase is used to remove the follicle cells which surround the oocytes . ... Properly de-folliculated oocytes should be well separated from one another,...

Hepatocytes

...oposed as important ... ... had no effect on FVIIa binding and internalization in hepatocytes . ... Rat hepatocytes were harvested by a two-step collagenase perfusion as described ... Cytokines & Cells Online Pathfinder Encyclopaedia ... Hepatocytes perform critical metabolic, endocrine, and secre...

Deoxyribonuclease

...I [Marsupenaeus jap... deoxyribonuclease I, putative [Aedes aegypti] Length = 313 Score = 257 bits (656) ... deoxyribonuclease . Methods: ... of collagenase or fibrinolysin/ deoxyribonuclease . ... trolled double-blind trial of fibrinolysin– deoxyribonuclease ... ...
Other Tags
(Date:7/11/2014)... MA (PRWEB) July 11, 2014 ... at least $50 billion in fuel costs ... immediately. The current GHG standards ... have taken it upon themselves to install ... include: , 1.    Idle reduction technologies , 2.    Efficient ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Ticket Down ... the Concord Pavilion . When it comes to the summer ... Bryan. The 37-year-old Georgia native is one of the biggest names ... entertainment business. Bryan is currently out on his “That’s My Kind ... many stops the tour will be making through the rest of ...
(Date:7/11/2014)... Global enterprises today are shifting towards ... management activities. Managed services offer these global enterprises a ... slowdown resulted into rising operational costs to companies. The ... to be the global market driver for expanding the ... managed services market is estimated to grow from $142.75 ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... (HealthDay News) -- Delaying surgery to repair damage to the ... middle of the knee -- could increase a young athlete,s ... medical records of 130 patients, aged 8 to 16, who ... less than six weeks after their injury, 37 had surgery ... more than three months after their injury. The youngsters ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
(Date:7/11/2014)... from Salk Institute for Biological Studies, BGI, and ... safety and reliability of the existing targeted gene ... TALEN-HDAdV, which could significantly increased gene-correction efficiency in ... published online in Cell Stell Cell ... gene therapy. , The combination of stem cells ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
Other Contents